|
| Author (year) | Proposed criteria | Pre-LT staging | Explant histology |
|
|
Yao et al. (2001) [88] | One tumor ≤6.5 cm
or ≤3 tumors each ≤4.5 cm
Total tumor diameter ≤8.5 cm | | 75.2% |
|
|
Cillo et al. (2004) [94] | Any size and number
No poorly differentiated tumor | 75% | |
|
|
Kneteman et al. (2004) [114] | One single tumor <7.5 cm
or any number <5 cm
Sirolimus as immunosuppressant | 82.9% (4-year-survival) | |
|
|
Ito et al. (2007) [95] | ≤10 tumor nodules
Tumor diameter ≤5 cm
PIVKA ≤400 mAU/mL
(LDLT) | 86.7% | |
|
|
Onaca et al. (2007) [115] | One tumor ≤6 cm
or ≤4 tumors each ≤5 cm | >60% | |
|
|
Lee et al. (2008) [96] | ≤6 tumor nodules
Tumor diameter ≤5 cm
No gross vascular invasion (LDLT) | | 76.3% |
|
|
Herrero et al. (2008) [97] | One tumor ≤6 cm
or ≤3 tumors ≤5 cm
No macrovascular invasion
No extrahepatic spread | 70% | |
|
|
Zheng et al. (2008) [113] | Total tumor diameter ≤8 cm
or total tumor diameter >8 cm,
Well differentiated, and AFP ≤400 ng/mL
No macrovascular invasion | | 72.3% |
|
|
Mazzaferro et al. (2009) [98] | Sum of size (largest tumor)
and number of nodules = 7 (up-to-seven)
No microvascular invasion | | 71.2% |
|
|
Muscari et al. (2009) [99] | ≤5 tumor nodules
Tumor diameter ≤5 cm | 77% | 76% |
|
|
Fujiki et al. (2009) [139] | ≤10 tumor nodules
Tumor diameter ≤5 cm
DCP values ≤ 400 mAU/mL | 89% | |
|
|
Dubay et al. (2011) [100] | Any size and number
No poor differentiated tumor | 72% | |
|
